|50.86||-0.9000||-1.74%||Vol 19.64K||1Y Perf -5.28%|
|Apr 16th, 2021 11:19 DELAYED|
|- -%||- -|
|Target Price||68.00||Analyst Rating||Hold 2.60|
|Potential %||33.23||Finscreener Ranking||★★★+ 52.57|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★★+ 58.73|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★+ 49.41|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||1.03B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||57.69||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-0.93|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||88.39K|
|Avg. Monthly Volume||127.41K|
|Avg. Quarterly Volume||148.90K|
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) stock closed at 51.76 per share at the end of the most recent trading day (a 2.19% change compared to the prior day closing price) with a volume of 111.03K shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Enanta Pharmaceuticals Inc. CEO is Jay R. Luly.
The one-year performance of Enanta Pharmaceuticals Inc. stock is -5.28%, while year-to-date (YTD) performance is 22.95%. ENTA stock has a five-year performance of 64.37%. Its 52-week range is between 40.32 and 58.59, which gives ENTA stock a 52-week price range ratio of 57.69%
Enanta Pharmaceuticals Inc. currently has a PE ratio of -17.10, a price-to-book (PB) ratio of 2.20, a price-to-sale (PS) ratio of 13.21, a price to cashflow ratio of 154.60, a PEG ratio of 2.32, a ROA of -11.17%, a ROC of -12.17% and a ROE of -11.86%. The company’s profit margin is -76.96%, its EBITDA margin is -62.20%, and its revenue ttm is $74.03 Million , which makes it $3.67 revenue per share.
Of the last four earnings reports from Enanta Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Enanta Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Enanta Pharmaceuticals Inc. is Hold (2.6), with a target price of $68, which is +33.23% compared to the current price. The earnings rating for Enanta Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enanta Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enanta Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.61, ATR14 : 2.34, CCI20 : 115.34, Chaikin Money Flow : -0.10, MACD : 0.12, Money Flow Index : 55.53, ROC : 5.03, RSI : 62.91, STOCH (14,3) : 77.80, STOCH RSI : 1.00, UO : 56.81, Williams %R : -22.20), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enanta Pharmaceuticals Inc. in the last 12-months were: Jay R. Luly (Option Excercise at a value of $0), Nathalie Adda (Option Excercise at a value of $0), Nathaniel S. Gardiner (Option Excercise at a value of $99 990), Paul J. Mellett (Option Excercise at a value of $10 949), Paul J. Mellett (Sold 6 000 shares of value $273 463 ), Yat Sun Or (Option Excercise at a value of $173 576)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.